F2R and chronic obstructive pulmonary disease: PAR-1 immunoreactivity was obtained in COPD patients by using two different monoclonal antibodies (ATAP2 and H111), mapping different epitopes of PAR-1, and gave us a useful method to evaluate the different levels of PAR-1 expression and activation in the airways of COPD patients.